×
About 3,025 results

ALLMedicine™ Angiosarcoma Center

Research & Reviews  1,035 results

Long-term disease-free survival of an undifferentiated pleomorphic sarcoma of the splee...
https://doi.org/10.1097/MD.0000000000031642
Medicine Tomioka A, Asakuma M et. al.

Dec 2nd, 2022 - Undifferentiated pleomorphic sarcoma (UPS) primarily occurs in the soft tissues of the extremities, trunk, and retroperitoneum. As the primary UPS of the spleen (splenic UPS) is extremely rare, to the best of our knowledge, only 19 cases have been...

Definitive Radiotherapy Using Electron Beam and Intensity-modulated Radiotherapy for Un...
https://doi.org/10.21873/anticanres.16110
Anticancer Research; Okano N, Yumisaki H et. al.

Dec 2nd, 2022 - Radiotherapy for angiosarcoma of the scalp has not been standardised yet. Hence, we aimed to retrospectively analyse the outcomes of patients treated with electron beam therapy or intensity-modulated radiation therapy (IMRT) for unresectable angio...

A review on the role of miR-210 in human disorders.
https://doi.org/10.1016/j.prp.2022.154244
Pathology, Research and Practice; Khalilian S, Bijanvand A et. al.

Nov 30th, 2022 - MicroRNA-210 (miR-210) is a miRNA with imperative effects in the pathophysiology of human disorders. miR-210 is encoded by MIR210 gene on chromosome 11p15.5. The stem-loop of this miRNA resides in an intron of the AK123483 noncoding RNA. This miRN...

Resolution of Disseminated Angiosarcoma in a Kidney Transplant Recipient After Treatmen...
https://doi.org/10.1016/j.transproceed.2022.09.029
Transplantation Proceedings; Friedman JK, Atari M et. al.

Nov 29th, 2022 - Angiosarcoma is a rare, almost universally fatal malignant neoplasm in kidney transplant recipients. No evidence-based guidelines are available for disseminated disease. Here, we report a case of a 66-year-old woman who developed disseminated angi...

Intravascular papillary endothelial hyperplasia of the spleen in a child: a case report.
https://doi.org/10.1186/s12880-022-00936-w
BMC Medical Imaging; Huang WP, Li LM et. al.

Nov 27th, 2022 - Intravascular papillary endothelial hyperplasia (IPEH) is a vascular tumor characterized by the proliferation of endothelial cells with papillary formation. It is a rare benign condition affecting the head and neck. Currently, no cases of IPEH of ...

see more →

Clinicaltrials.gov  37 results

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04339738

Oct 5th, 2022 - PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane naive angiosarcoma. II. To determine the overall response rate (ORR) of nivolumab in combination with cabozan...

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT03860272

Sep 16th, 2022 - This Phase 1 study will enroll up to approximately 195 evaluable adult participants with refractory cancer (solid tumors) regardless of diagnosis. The study will consist of a 3+3 dose escalation. Different dose levels of botensilimab, both monothe...

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT04859465

Sep 7th, 2022 - Soft tissue sarcoma (STS) is a relatively rare malignant tumor. In recent years, the disease has been increasing gradually. As an important biological feature of soft tissue sarcoma is local recurrence and distant metastasis, most patients die of ...

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT03921073

Aug 22nd, 2022 - This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
https://clinicaltrials.gov/ct2/show/NCT01462630

Aug 19th, 2022 - PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) at 3 months and response rate defined as complete response (CR) and partial response (PR) in angiosarcoma patients treated with pazopanib. SECONDARY OBJECTIVES: I. To assess o...

see more →

News  115 results

Immunotherapy May Represent an Exciting Development in Angiosarcoma Treatment
https://www.onclive.com/view/immunotherapy-may-represent-an-exciting-development-in-angiosarcoma-treatment

Oct 21st, 2022 - Although systemic treatments are utilized for angiosarcoma, an aggressive and rare subset of a rare cancer, the efficacy achieved with these options is not as good as it needs to be. Immunotherapy may be able to address the unmet need for a system...

This One Risk Factor Dominates for Soft Tissue Sarcoma After Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/101210

Oct 13th, 2022 - Although relatively rare, soft tissue sarcoma after breast cancer treatment was linked most strongly to treatment with radiation, according to data from two large U.S. cohorts of breast cancer survivors. Radiotherapy was associated with an 8.1-fol...

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas
https://www.onclive.com/view/durvalumab-plus-tremelimumab-elicits-favorable-pfs-rates-in-advanced-sarcomas

Aug 23rd, 2022 - The combination of durvalumab (Imfinzi) and tremelimumab demonstrated positive progression-free survival (PFS) and overall survival (OS) rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas, accor...

Oral Paclitaxel-Encequidar Elicits Responses in Radiation-Associated Breast Angiosarcoma
https://www.onclive.com/view/oral-paclitaxel-encequidar-elicits-responses-in-radiation-associated-breast-angiosarcoma

Aug 12th, 2022 - Oral paclitaxel in combination with encequidar (oPac+E) may provide patients with radiation-associated breast angiosarcoma an effective treatment, according to study results presented at the 2020 San Antonio Breast Cancer Symposium.1 The research...

Dr. Wagner on Responses Achieved With Nivolumab/Ipilimumab in Angiosarcoma
https://www.onclive.com/view/dr-wagner-on-responses-achieved-with-nivolumab-ipilimumab-in-angiosarcoma

Aug 12th, 2022 - Michael Wagner, MD, an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Research Center, discusses responses achieved in the phase 2 DART trial with nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with angios...

see more →

Patient Education  23 results see all →